15.56
+0.39(+2.57%)
Currency In USD
| Previous Close | 15.17 |
| Open | 15.3 |
| Day High | 15.81 |
| Day Low | 15.19 |
| 52-Week High | 72.37 |
| 52-Week Low | 9.12 |
| Volume | 646,019 |
| Average Volume | 531,266 |
| Market Cap | 631.98M |
| PE | 48.63 |
| EPS | 0.32 |
| Moving Average 50 Days | 14.01 |
| Moving Average 200 Days | 20.02 |
| Change | 0.39 |
If you invested $1000 in Keros Therapeutics, Inc. (KROS) since IPO date, it would be worth $774.9 as of August 23, 2025 at a share price of $15.56. Whereas If you bought $1000 worth of Keros Therapeutics, Inc. (KROS) shares 3 years ago, it would be worth $418.62 as of August 23, 2025 at a share price of $15.56.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
GlobeNewswire Inc.
Aug 20, 2025 1:48 PM GMT
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with di
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
GlobeNewswire Inc.
Aug 06, 2025 8:15 PM GMT
Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutic
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
GlobeNewswire Inc.
Jul 17, 2025 12:00 PM GMT
Milestone payment of $10 million triggered under the global license agreement with TakedaLEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on de